PF-06747775 is another small molecule inhibitor of EGFR T790M with minimal activity against wild-type EGFR. It is being studied in a phase I/II clinical trial (NCT02349633) in advanced NSCLC patients with EGFR mutations (Del19 or L858R ± T790M). This evidence concerns the gene EGFR and non-small cell lung carcinoma.